Peijuan Zhu

Publications by Year

Research Areas

Biosimilars and Bioanalytical Methods, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Resistance in Bacteria, Pneumonia and Respiratory Infections, Statistical Methods in Clinical Trials

Most-Cited Works

• → Implementation and testing of stable, fast implicit solvation in molecular dynamics using the smooth‐permittivity finite difference Poisson–Boltzmann method(2004)107 cited
• → CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy(2024)101 cited
• → A retention‐time‐shift‐tolerant background subtraction and noise reduction algorithm (BgS‐NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices(2009)79 cited
• → Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study(2017)79 cited
• → Determination of cellular redox status by stable isotope dilution liquid chromatography/mass spectrometry analysis of glutathione and glutathione disulfide(2008)77 cited
• → An Accurate-Mass-Based Spectral-Averaging Isotope-Pattern-Filtering Algorithm for Extraction of Drug Metabolites Possessing a Distinct Isotope Pattern from LC-MS Data(2009)75 cited
• → Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease(2006)69 cited
• → 15-oxo-Eicosatetraenoic Acid, a Metabolite of Macrophage 15-Hydroxyprostaglandin Dehydrogenase That Inhibits Endothelial Cell Proliferation(2009)69 cited
• → A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis(2017)61 cited
• → Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.(2014)44 cited